The Relationship Between SARS-CoV-2 Neutralizing Antibody Titers and Avidity in Plasma Collected From Convalescent Nonvaccinated and Vaccinated Blood Donors
Open Access
- 27 March 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 228 (3), 245-250
- https://doi.org/10.1093/infdis/jiad070
Abstract
Convalescent plasma (CP) treatment of coronavirus disease 2019 (COVID-19) has shown significant therapeutic effect when administered early (eg, Argentinian trial showing reduced hospitalization) but has in general been ineffective (eg, REMAP-CAP trial without improvement during hospitalization). To investigate whether the differences in CP used could explain the different outcomes, we compared neutralizing antibodies, anti-spike IgG, and avidity of CP used in the REMAP-CAP and Argentinian trials and in convalescent vaccinees. We found no difference between the trial plasmas, emphasizing initial patient serostatus as treatment efficacy predictor. By contrast, vaccinee CP showed significantly higher titers and avidity, being preferable for future CP treatment. Clinical Trials Registration. NCT02735707 and NCT04479163.Keywords
Funding Information
- Support-E
- National Institute for Health and Care Research
- Academy of Finland
- Finnish Society for Study of Infectious Diseases
- NHS Blood and Transplant
- Sigrid Juselius Foundation
- Magnus Ehrnrooth Foundation
This publication has 15 references indexed in Scilit:
- Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trialThe Lancet, 2022
- Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trialsBMC Infectious Diseases, 2021
- Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19JAMA, 2021
- Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trialNature Medicine, 2021
- Comparison of approaches for IgG avidity calculation and a new highly sensitive and specific method with broad dynamic rangeInternational Journal of Infectious Diseases, 2021
- SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial dataEurosurveillance, 2021
- Longitudinal antibody repertoire in “mild” versus “severe” COVID-19 patients reveals immune markers associated with disease severity and resolutionScience Advances, 2021
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older AdultsThe New England Journal of Medicine, 2021
- A 10-Minute “Mix and Read” Antibody Assay for SARS-CoV-2Viruses, 2021
- Convalescent plasma therapy for the treatment of patients with COVID‐19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levelsTransfusion Medicine, 2020